Peptide double agoniste pour la recherche métabolique avancée.
Tirzepatide is a novel dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist. It represents a new class of incretin-based therapeutics with enhanced efficacy compared to single-receptor agonists.
Key Research Areas:
• Superior glycemic control
• Significant weight reduction
• Improved insulin sensitivity
• Cardiovascular benefits
• Metabolic optimization
Clinical trials have shown tirzepatide to produce unprecedented weight loss results compared to other incretin-based therapies.
RESEARCH USE ONLY: All products sold on this website are intended for laboratory and research purposes only. These products are NOT intended for human or animal consumption.
